Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Daniela, Lang, Michael, Harth, Andreas, Naumann, Markus, Weber, Frank, Tumani, Hayrettin, Bayas, Antonios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519865/
https://www.ncbi.nlm.nih.gov/pubmed/26132570
http://dx.doi.org/10.3390/ijms160714669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519865/
https://www.ncbi.nlm.nih.gov/pubmed/26132570
http://dx.doi.org/10.3390/ijms160714669

Ejemplares similares